From joint ventures to licensing deals, biotechnology is emerging as a strategic bridge between China and Japan.

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...

Pariet is a proton pump inhibitor (PPI) discovered and developed by Eisai, approved in more than 100 countries and regions worldwide. Pariet was approved in China in 2000 and is indicated ...